Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

n, of which $8.5 million was related to cost sharing and $18.1 million was related to the Excess Amounts, which are due to be received during our quarter ending March 31, 2013. At June 30, 2012, the Company had $5.8 million due from Janssen related to cost sharing. At September 30, 2012, the Company had cash, cash equivalents and marketable securities of $286.1 million.

The Company expects to end calendar year 2013 with cash, cash equivalents and marketable securities of more than $225 million.

"Ibrutinib has demonstrated great clinical progress during this past year. Today we have a very solid development program in place with 5 Phase III trials initiated and several more trials to be started this year. We were honored to announce this past Tuesday that ibrutinib received Breakthrough Designation in two B-cell malignancies. We look forward to working with the FDA to bring this therapy to market in a timely manner," said Bob Duggan, CEO and Chairman of the Board. "Looking ahead, our goals for this year are star high as we are continuing to unfold our clinical program. With our partner Janssen, we are committed to a shared vision of patient friendly, body harmonious solutions intended to improve the quality of life, increase duration of life and resolve serious medical health care needs for patients."

Recent Developments & HighlightsBreakthrough Therapy Designation

The Breakthrough Therapy Designation is intended to expedite the development and review of a potential new drug for serious or life-threatening diseases where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation of a drug as a Breakthrough Therapy was enacted as part of the 2012 Food and Drug Administration Safety and Innovation Act.

Pharmacyclics, together
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... and SAN JOSE, California , January 15, ... developing antibody-drug conjugates for cancer, today announced the appointment of ... Dr Reynolds has over 20 years, development experience gained in ... Seattle Genetics. "I am delighted to welcome Tom ...
(Date:1/15/2014)... More than 5 million Americans are ... 3 seniors will die with Alzheimer’s or another dementia, ... have shocked many Americans into looking for ways to ... tragic age-related cognitive disorders. Jonathan Weisman, president of Biohack ...
(Date:1/15/2014)... 2013 was a banner year of continued ... saw continued independent research led by the team at ... $1 million grant from the Susanne Marcus Collins Foundation, ... peer reviewed journal, Amy Grant highlighted Brainwave Optimization® in ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. ... Road, Warrington, Pa. , Details: The Hepatitis B ... a cure for hepatitis B and improving the quality of ... Ball on Friday, April 11 at Warrington Country Club in ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2
... ArborGen, LLC, a leader in forest tree ... field trials that are utilizing technology in-licensed from Senesco ... The two companies had previously announced that trees that ... in 3-year-old field trials. , , Selected ...
... published in July 7, 2009 Issue of Proceedings of the ... QUEBEC CITY, July 7 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... focused on endocrine therapy and oncology, today announced publication in ... of Sciences (PNAS), of new data supporting the use of ...
... Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ... treatments for human disease, announced today that it has initiated ... , the company,s oral drug candidate for managing gastrointestinal symptoms ... is designed to reduce serotonin production in patients with metastatic ...
Cached Biology Technology:ArborGen and Senesco Announce Wood Quality Results 2ArborGen and Senesco Announce Wood Quality Results 3ArborGen and Senesco Announce Wood Quality Results 4AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction 2AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction 3AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction 4Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome 2Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome 3Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome 4
(Date:4/23/2014)... new study from the Indiana University School of Public ... and heart disease by finding a strong association between ... coronary heart disease. , The study found that heme ... by 57 percent, while no association was found between ... sources, and coronary heart disease. , The study was ...
(Date:4/23/2014)... and Spanish . ... released its Conservation Assessment for the Big Bend-Ro Bravo ... 29 priority conservation areas in a region straddling the ... in the states of Texas, Coahuila, and Chihuahua. This ... inhabited by rare and endangered plants and animals, and ...
(Date:4/23/2014)... evidence that the source of a unique rhythmic sound, ... the "bio-duck," is the Antarctic minke whale ( Balaenoptera ... in the 1960s who thought it sounded like a ... locations in the Southern Ocean, but its source has ... an international team of researchers deployed acoustic tags on ...
Breaking Biology News(10 mins):Study: Iron consumption can increase risk for heart disease 2Conservation priorities released for several protected areas along US-Mexico border 2Conservation priorities released for several protected areas along US-Mexico border 3Scientists identify source of mysterious sound in the Southern Ocean 2Scientists identify source of mysterious sound in the Southern Ocean 3
... YORK, NY and PALO ALTO, CA January 22, 2009 ... four young scientists with novel approaches to fighting cancer have ... of $450,000 over three years is awarded each year to ... have a major impact on the prevention, diagnosis and treatment ...
... 22, 2009--Biotechnology companies are building on what they ... decade and are expected to drive this market ... Genetic Engineering and Biotechnology News ( GEN ... number of advantages, including reducing reagent consumption, increasing ...
... three-year study to conserve and restore endangered horse mussel ... the University,s marine research and outreach centre in Portaferry ... of Biological Sciences, will provide scientific and technological research ... to restore it. Horse mussel reefs are important ...
Cached Biology News:2009 Damon Runyon-Rachleff Innovation Awards granted for pioneering ideas in cancer research 22009 Damon Runyon-Rachleff Innovation Awards granted for pioneering ideas in cancer research 32009 Damon Runyon-Rachleff Innovation Awards granted for pioneering ideas in cancer research 4GEN reports on growing reliance on microfluidics technology 2Queen's University Belfast works to save Strangford horse mussels 2
B2-Microgloulin...
... utilizies CTI Molecular Imaging's proprietary Focus™ detector ... volume as the R4. The microPET ... any commerically avaiable PET scanner. Focus ... of any scinitallor based PETsystems. The ...
...
... product has been developed to significantly increase ... proteins. Stability is increased at room ... centigrade. This product is subjected to ... or azide. This formulation insures consistently ...
Biology Products: